Skip to main content

Polaris Partners — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

186
Companies
$7.2B
Total invested
$53.1M
Avg. check
36
Industries
Biotechnology 16Health Care 11Medical 7Therapeutics 5Biopharma 4Software 3+30 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 186
Ankyra
November 2021

Ankyra is a biotech company developing anchored immunotherapy for cancer treatments.

Biotechnology · Boston$45.0M Series B
Zag Bio
October 2025

Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases.

Biopharma · Cambridge$80.0M Series A
Sonrai Security
October 2021

Sonrai Security delivers enterprise cloud security for companies running on AWS, Azure, and Google Cloud.

Cloud Data Services · New York$50.0M Series C
B12
October 2021

B12 offers website building, contact management, online scheduling, payments, invoicing, and SEO services.

Artificial Intelligence (AI) · New York$15.7M Series A
Sunbird Bio
October 2024

Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes.

Biotechnology · Singapore$14.0M Venture - Series Unknown
Folx Health
October 2022

Folx Health is a telehealth platform that provides digital healthcare services designed for the LGBTQIA+ community.

Health Care · Boston$30.0M Series B
Tropic Biosciences
March 2026

Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.

Agriculture · London$105.0M Series C
BarkBox
January 2026

Barkbox is a monthly subscription service platform that provides dog products.

E-Commerce · New York$35.0M Post Ipo Debt
Mesodyne
January 2026

Mesodyne manufactures the LightCell: a high energy density, silent, compact power generator converting any fuel to electricity via light.

Energy · SomervilleGrant
TRex Bio
January 2026

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

Bioinformatics · South San Francisco$50.0M Series Unknown
Primmune Therapeutics
January 2026

Primmune Therapeutics is a Biotechnology company.

Biotechnology · San Diego$23.3M Series B
Muna Therapeutics
January 2026

Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

Biopharma · Copenhagen$1.0M Grant
EpiBiologics
January 2026

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

Biotechnology · San Mateo$107.0M Series B
Nomad Health
December 2025

Nomad Health is an online staffing marketplace that connects clinicians to healthcare jobs.

Health Care · New York$33.8M Series Unknown
Invivyd
November 2025

Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.

Biotechnology · Waltham$125.0M Post Ipo Equity
Proof
November 2025

Proof is an identity-assured transaction management platform that verifies identities and secures digital transactions.

Legal · Boston$15.7M Series Unknown
Sovato Health
November 2025

Sovato Health provides surgical access through remote robotic surgeon options.

Health Care · Santa Barbara$41.0M Series B
Indomo
October 2025

Indomo is a clinical-stage firm that aims to improve access to quality healthcare through novel device-enabled treatments.

Biotechnology · San Francisco$25.0M Seed
Leyden Labs
October 2025

Leyden Labs provides a platform that targets commonalities of viral families to protect humanity from known and future viruses.

Biotechnology · Amsterdam$35.2M Series Unknown
Crossbow Therapeutics
September 2025

Crossbow Therapeutics is a biotech company developing a new type of cancer treatment.

Biotechnology · Cambridge$30.3M Series Unknown
Volastra Therapeutics
September 2025

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.

Biotechnology · New York$30.1M Series A
Cirrus Therapeutics
August 2025

Cirrus Therapeutics is a Biotechnology Research firm diganosing and treating eye diseases affecting ocular immune system.

Biotechnology · Cambridge$11.0M Seed
Compass Therapeutics
August 2025

Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.

Biopharma · Boston$120.0M Post Ipo Equity
Auron Therapeutics
July 2025

Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Biotechnology · NewtonSeries Unknown

Where Polaris Partners invests

Biotechnology16
Health Care11
Medical7
Therapeutics5
Biopharma4
Software3

About Polaris Partners's portfolio

How many companies has Polaris Partners invested in?

Polaris Partners has invested in 186 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Polaris Partners invest in?

Polaris Partners's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 36 different industry categories.

What is Polaris Partners's largest investment?

Among tracked funding rounds, Invivyd received $125.0M in a Post Ipo Equity round. Polaris Partners's total known invested capital is $7.2B.

What is the average investment size for Polaris Partners?

Polaris Partners's average investment size is $53.1M across its portfolio of 186 companies.

What are Polaris Partners's most recent investments?

Recent Polaris Partners portfolio additions include Ankyra, Zag Bio, Sonrai Security, B12, Sunbird Bio. These companies were founded in 2020 or later.

Reach the founders behind these 186 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →